Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

MALDI-FTMS Imaging

By Drug Discovery Trends Editor | March 11, 2008

Bruker Daltronics apex ultraEditors at Pittcon awarded an honorable mention to Bruker Daltonics’ apex-ultra MALDI-FTMS platform for drug and metabolite tissue imaging at therapeutic dosing levels. The high sensitivity SmartBeam MALDI ion funnel source, coupled with ultra-high mass resolution FTMS make the apex-ultra ideally suited for tissue imaging of small molecules, including drugs from animals dosed at therapeutic levels, e.g. at 5 mg/kg and lower, according to the company.

The MALDI source of the apex-ultra is the Apollo II dual ESI/MALDI source based on the patented ion funnel technology, which provides the combination of high sensitivity with a one-mouse-click changeover between ESI and MALDI. The addition of the SmartBeam laser technology, developed initially for the Bruker Flex line of TOF/TOFs, creates a MALDI source that provides the necessary 200 Hz repetition rate laser and less than 40 micron spot size, as well as brilliant spectra quality. SmartBeam is also compatible with the full range of matrix choices for MALDI.

The performance of the apex-ultra in the low-m/z region (150 – 2,000 m/z) is exceptional and does not suffer from complications of matrix background, the company reports. With mass resolution greater than 900,000 (at 7 Tesla), the cluttered spectra produced in MALDI imaging of tissue samples are readily dissected, allowing for the first time MALDI-MS imaging of small molecules without the requirement to go to tandem mass spectrometry (MS/MS or TOF/TOF) for chemical background suppression. This sensitivity and throughput is due to the enhanced FTMS peak capacity, and is crucial for small molecule imaging in which crowded spectra with closely spaced peak interferences are the norm rather than the exception. In addition, Bruker’s SmartFormula software automatically provides empirical formulae identification for detected molecules.

www.bruker.com


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE